Hormone replacement therapy and breast cancer incidence in Korean women

被引:2
作者
Choi, Euna [1 ]
Lee, Jae Kyung [1 ]
Baek, Jin Kyung [1 ]
Chung, Yunsoo [1 ]
Kim, Heeyon [1 ]
Yun, Bo Hyon [1 ]
Seo, Seok Kyo [1 ,2 ]
机构
[1] Yonsei Univ, Coll Med, Severance Hosp, Dept Obstet & Gynecol, Seoul, South Korea
[2] Yonsei Univ, Severance Hosp, Coll Med, Dept Obstet & Gynecol, 50 Yonsei Ro, Seoul 03722, South Korea
关键词
Menopausal hormone therapy; Estrogen -progesterone therapy; Tibolone; Breast cancer; Menopause; ESTROGEN; TIBOLONE; TRENDS; PROGESTIN; RISK;
D O I
10.1016/j.maturitas.2024.107946
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objectives: After the 2002 Women's Health Initiative (WHI) study, the global use of menopausal hormone therapy (MHT) declined, and despite subsequent studies indicating a low risk of breast cancer, concerns about MHT usage persist. We examined the relationship between changes in MHT use and changes in the incidence of breast cancer from 2002 to 2020 in South Korea. Study design: This study used tumor registry information from 2002 to 2020 from the Korean Statistical Information Service and analyzed the incidence rate of invasive breast cancer in women, who were divided into two age groups: <50 and >50 years. The numbers of MHT prescriptions in Korea between 2002 and 2020 was determined from pharmacy data. Results: The incidence of breast cancer per 100,000 women in South Korea increased from 34.3 in 2002 to 96.4 in 2020. Breast cancer incidence rates increased annually in both groups of women (those aged under and over 50 years), with no significant difference between the two (p = 0.614). Prescriptions for estrogen therapy (ET) in 2020 were 52.7 % lower than those in 2002. Prescriptions for estrogen -progesterone therapy (EPT) decreased by 27.9 % over the same period. Conversely, tibolone prescriptions, which had initially decreased by 25.4 % in 2004, subsequently showed a steady increase and were 93.6 % higher in 2020 than in 2002. Conclusion: The incidence of breast cancer increased annually in Korean women of all ages; however, the use of ET and EPT for MHT has declined since 2002, particularly the use of EPT after 2010. MHT, especially EPT, did not significantly increase the incidence of breast cancer in Korean women.
引用
收藏
页数:7
相关论文
共 32 条
  • [21] Retrospective observation on contribution and limitations of screening for breast cancer with mammography in Korea: detection rate of breast cancer and incidence rate of interval cancer of the breast
    Lee, Kunsei
    Kim, Hyeongsu
    Lee, Jung Hyun
    Jeong, Hyoseon
    Shin, Soon Ae
    Han, Taehwa
    Seo, Young Lan
    Yoo, Youngbum
    Nam, Sang Eun
    Park, Jong Heon
    Park, Yoo Mi
    [J]. BMC WOMENS HEALTH, 2016, 16
  • [22] Hormone-replacement therapy: current thinking
    Lobo, Roger A.
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2017, 13 (04) : 220 - 231
  • [23] Mizukoshi Miwa Mia, 2020, Asian Pac J Cancer Prev, V21, P2123, DOI 10.31557/APJCP.2020.21.7.2123
  • [24] National Cancer Information Center, About Us
  • [25] Opatrny L, 2008, BJOG-INT J OBSTET GY, V115, P169, DOI 10.1111/j.1471-0528.2007.01520.x
  • [26] Age at natural menopause in Koreans: secular trends and influences thereon
    Park, Chan Young
    Lim, Joong-Yeon
    Park, Hyun-Young
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2018, 25 (04): : 423 - 429
  • [27] The decrease in breast-cancer incidence in 2003 in the United States.
    Ravdin, Peter M.
    Cronin, Kathleen A.
    Howlader, Nadia
    Berg, Christine D.
    Chlebowski, Rowan T.
    Feuer, Eric J.
    Edwards, Brenda K.
    Berry, Donald A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (16) : 1670 - 1674
  • [28] Postmenopausal hormone therapy and the risk of breast cancer in Norway
    Roman, Marta
    Sakshaug, Solveig
    Graff-Iversen, Sidsel
    Vangen, Siri
    Weiderpass, Elisabete
    Ursin, Giske
    Hofvind, Solveig
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (03) : 584 - 593
  • [29] Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial
    Rossouw, JE
    Anderson, GL
    Prentice, RL
    LaCroix, AZ
    Kooperberg, C
    Stefanick, ML
    Jackson, RD
    Beresford, SAA
    Howard, BV
    Johnson, KC
    Kotchen, JM
    Ockene, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (03): : 321 - 333
  • [30] Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
    Schairer, C
    Lubin, J
    Troisi, R
    Sturgeon, S
    Brinton, L
    Hoover, R
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (04): : 485 - 491